HAVN Life Sciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HAVLF research report →
About the company
HAVN Life Sciences Inc. is a biotechnology firm that specializes in the research and innovation of psychotropic compounds derived from botanical and fungal organisms. The company is also dedicated to establishing standardized, quality-controlled methodologies for extracting these psychoactive molecules, with a specific focus on Psilocybe mushroom species and their key constituents such as psilocybin, psilocin, and baeocystin.
- CEO
- Tim Moore
- IPO
- 2021
- Employees
- 6
- HQ
- Port Moody, BC, CA
Price Chart
- Market Cap
- $2.56K
- P/E
- -0.01
- P/S
- 4.17
- P/B
- 0.04
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
- Gross Margin
- 32.44%
- Op Margin
- -3548.44%
- Net Margin
- -8117.81%
- ROE
- -274.69%
- ROIC
- -277.90%
- Revenue
- $276.47K · 0.00%
- Net Income
- $-22,443,548 · 26.13%
- EPS
- $-5.25 · 38.02%
- Op Income
- $-9,810,466
- FCF YoY
- 23.69%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.29
- Avg Volume
- 14.27K
Get TickerSpark's AI analysis on HAVLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HAVLF coverage
Recent articles, reports, and earnings notes.
No research on HAVLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HAVLF report →Similar companies
Peers in the same neighborhood.